Abstract
Purpose
Methods
Findings
Implications
Key words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsReferences
National Center for Chronic Disease Prevention and Health Promotion. Heart Disease and Stroke Prevention: Addressing the National’s Leading Killers. At a Glance (2011). Centers for Disease Control. http://198.246.124.29/chronicdisease/resources/publications/aag/pdf/2011/heart-disease-and-stroke-aag-2011.pdf. Accessed April 20, 2015.
- 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines.J Am Coll Cardiol. 2014; 63: 2889-2934
- National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 – Executive Summary.J Clin Lipidol. 2014; 8: 473-488
- Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).Circulation. 2002; 106: 3143-3421
- N–3 fatty acids in patients with multiple cardiovascular risk factors.N Engl J Med. 2013; 368: 1800-1808
- Effects of extended-release niacin with laropiprant in high-risk patients.N Engl J Med. 2014; 371: 203-212
- Effects of combination lipid therapy in type 2 diabetes mellitus.N Engl J Med. 2010; 362: 1563-1574
- Mechanism of action of niacin.Am J Cardiol. 2008; 101: 20B-26B
- Clofibrate and niacin in coronary heart disease.JAMA. 1975; 231: 360-381
- Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.J Am Coll Cardiol. 1986; 8: 1245-1255
- Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid.Acta Med Scand. 1988; 223: 405-418
- Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts.JAMA. 1987; 257: 3233-3240
- Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up.JAMA. 1990; 264: 3013-3017
- Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.N Engl J Med. 1991; 325: 599-605
- Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease.N Engl J Med. 2001; 345: 1583-1592
- Arterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins.Circulation. 2004; 110: 3512-3517
- Extended-release niacin or ezetimibe and carotid intima-media thickness.N Engl J Med. 2009; 361: 2113-2122
- A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.Ann Intern Med. 2005; 142: 95-104
- Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.N Engl J Med. 2011; 365: 2255-2267
- Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.J Cardiovasc Pharmacol Ther. 2010; 15: 158-166
- Extended-release niacin therapy and risk of ischemic stroke in patients with cardiovascular disease–the Atherothrombosis Intervention in Metabolic Syndrome with low HDL/high triglycerides: impact on global health outcome (AIM-HIGH) trial.Stroke. 2013; 44: 2688-2693
- The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.J Am Coll Cardiol. 2013; 61: 440-446
- Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.Expert Rev Cardiovasc Ther. 2008; 6: 391-409
- Overview of omega-3 fatty acid therapies.PT. 2013; 38: 681-691
- Omega-3 polyunsaturated fatty acids and cardiovascular diseases.J Am Coll Cardiol. 2009; 54: 585-594
- Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.Circulation. 2004; 110: 227-239
- Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.J Clin Endocrinol Metab. 2012; 97: 2969-2989
- Usefulness of omega-3 fatty acids and the prevention of coronary heart disease.Am J Cardiol. 2005; 96: 1521-1529
- n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review.Am J Clin Nutr. 2006; 84: 5-17
- Alpha-linolenic acid: is it essential to cardiovascular health?.Curr Atheroscler Rep. 2010; 12: 359-367
- Long chain omega-3 dietary supplements: a review of the National Library of Medicine Herbal Supplement Database.Metab Syndr Relat Disord. 2011; 9: 255-271
- Overview of prescription omega-3 fatty acid products for hypertriglyceridemia.Postgrad Med. 2014; 126: 7-18
- Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART).Lancet. 1989; 2: 757-761
- Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the gissi-prevenzione trial. Gruppo Italiano per lo Studio Della Sopravvivenza Nell’infarto Miocardico.Lancet. 1999; 354: 447-455
- Lack of benefit of dietary advice to men with angina: results of a controlled trial.Eur J Clin Nutr. 2003; 57: 193-200
- Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.Lancet. 2007; 369: 1090-1098
- Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.Lancet. 2008; 372: 1223-1230
- N-3 fatty acids and cardiovascular events after myocardial infarction.N Engl J Med. 2010; 363: 2015-2026
- OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.Circulation. 2010; 122: 2152-2159
- Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.BMJ. 2010; 341: c6273
- The ORIGIN Trial Investigators. n–3 fatty acids and cardiovascular outcomes in patients with dysglycemia.N Engl J Med. 2012; 367: 309-318
- Fish and omega-3 fatty acid intake and risk of coronary heart disease in women.JAMA. 2002; 287: 1815-1821
- Fish consumption and risk of sudden cardiac death.JAMA. 1998; 279: 23-28
- ω-3 Fatty acids, atherosclerosis progression and cardiovascular outcomes in recent trials: new pieces in a complex puzzle.Heart. 2014; 100: 530-533
- Effects of omega-3 fatty acid for sudden cardiac death prevention in patients with cardiovascular disease: a contemporary meta-analysis of randomized, controlled trials.Cardiovasc Drugs Ther. 2011; 25: 259-265
- Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus.Cochrane Database Syst Rev. 2008; (Issue 1. Art No:D003205)
- Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis.JAMA. 2012; 308: 1024-1033
- Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials.Arch Intern Med. 2012; 172: 686-694
- Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis.Circ Cardiovasc Qual Outcomes. 2012; 5: 808-818
- Systematic review on evidence of the effectiveness of cholesterol-lowering drugs.Adv Ther. 2010; 27: 348-364
- Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials.BMC Cardiovasc Disord. 2010; 10: 24
- The impact of omega-3 polyunsaturated fatty acid supplementation on the incidence of cardiovascular events and complications in peripheral arterial disease: a systematic review and meta-analysis.BMC Cardiovasc Disord. 2014; 14: 70
- Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis.BMJ. 2012; 345: e6698
- Fish oils in the care of coronary heart disease patients: a meta-analysis of randomized controlled trials.Fundam Clin Pharmacol. 2004; 18: 581-592
- Omega 3 fatty acids for prevention and treatment of cardiovascular disease.Cochrane Database Syst Rev. 2004; (Issue 4. Art. No:CD003177)
- Effect of different antilipidemic agents and diets on mortality: a systematic review.Arch Intern Med. 2005; 165: 725-730
- Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: a meta-analysis of randomized controlled trials.Ann Med. 2009; 41: 301-310
- Long chain omega-3 fatty acids and cardiovascular disease: a systematic review.Br J Nutr. 2012; 107: S201-S213
- Exploring newer cardioprotective strategies: n-3 fatty acids in perspective.Thromb Haemost. 2010; 104: 664-680
- The use of fibric acid derivatives in cardiovascular prevention.Curr Treat Options Cardiovasc Med. 2011; 13: 335-342
- Cardiometabolic impact of non-statin lipid lowering therapies.Curr Atheroscler Rep. 2014; 16: 390
- Combined therapy in the treatment of dyslipidemia.Fundam Clin Pharmacol. 2010; 24: 19-28
- Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study.Circulation. 2000; 102: 21-27
- Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia.N Engl J Med. 1987; 317: 1237-1245
- Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.N Engl J Med. 1999; 341: 410-418
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial.Lancet. 2005; 366: 1849-1861
- Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region.BMJ. 1971; 4: 767-775
- Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians.BMJ. 1971; 4: 775-784
- Controlled trial of clofibrate in cerebral vascular disease.Atherosclerosis. 1972; 15: 177-183
- The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section.Stroke. 1973; 4: 684-693
- Cooperative trial committee of principal investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.Br Heart J. 1978; 40: 1069-1118
- Diabetes Intervention Study. Multi-intervention trial in newly diagnosed NIDDM.Diabetes Care. 1991; 14: 308-317
- Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study.Circulation. 1995; 92: 1779-1785
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.Lancet. 2010; 375: 1875-1884
- Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.J Am Coll Cardiol. 2005; 45: 185-197
- Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials.Curr Med Res Opin. 2006; 22: 617-623
- Effects of fibrates in kidney disease: a systematic review and meta-analysis.J Am Coll Cardiol. 2012; 60: 2061-2071
- Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.Am J Med. 2009; 122: 962.e1-962.e8
- Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients.BMJ. 2014; 349: g4379
- Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy.Ann Intern Med. 2014; 160: 468-476
- Effect of different antilipidemic agents and diets on mortality: a systematic review.Arch Intern Med. 2005; 165: 725-730
- Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus - a pooled meta-analysis of randomized placebo-controlled clinical trials.Int J Cardiol. 2010; 141: 157-166
- Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.Arch Intern Med. 2003; 163: 669-676
- Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention.BMC Neurol. 2013; 13: 1
- Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.Atherosclerosis. 2011; 217: 492-498
- Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis.J Cardiovasc Pharmacol. 2011; 57: 267-272
- Fibrates for primary prevention of cardiovascular disease events.Cochrane Database Syst Rev. 2012; (Issue 3. Art No:CD009753)
- Bile acid sequestrants: mechanisms of action on bile acid and cholesterol metabolism.Eur J Clin Pharmacol. 1991; 40: S53-S58
Monroe AK, Gudzune KA, Sharma R, et al. Combination Therapy Versus Intensification of Statin Monotherapy: An Update, Comparative Effectiveness Review No 132. AHRQ Publication No. 14-EHC013-EF. Rockville, MD: Agency for Healthcare Research and Quality; February 2014. http://www.ncbi.nlm.nih.gov/books/NBK189822/. Accessed April 22, 2015.
- Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice.Am J Cardiol. 2007; 99: 530-534
- The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.JAMA. 1984; 251: 365-374
- Colestipol hydrochloride in hypercholesteroleamic patients- effect on serum cholesterol and mortality.J Chronic Dis. 1978; 31: 5-14
- Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy.Am J Cardiol. 1995; 75: 34-39
- Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia.Am J Med. 2001; 110: 352-360
- Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively.Atherosclerosis. 2001; 158: 407-416
- Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia.Arch Intern Med. 1993; 153: 1321-1329
- Effects of pravastatin and cholestyramine on circulating levels of parathyroid hormone and vitamin D metabolites.Clin Ther. 1990; 12: 427-430
- Effect of pravastatin and cholestyramine on triglyceride-rich lipoprotein particles and Lp(a) in patients with type II hypercholesterolemia.Drug Development Res. 1992; 27: 297-306
- Low-dose combination therapy with colestipol and simvastatin in patients with moderate to severe hypercholesterolemia.Nutr Metab Cardiovasc Dis. 1995; 5: 39-44
- Ezetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 years.Curr Vasc Pharmacol. 2011; 9: 62-86
- Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study.J Cardiovasc Pharmacol Ther. 2012; 18: 5-12
- Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia.Ann Intern Med. 2009; 151: 622-630
- Safety and coadministration of ezetimibe and statins in patients with hypercholesterolemia: a meta-analysis.Intern Med J. 2015; 45: 546-557
- Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study.Am J Cardiol. 2007; 99: 970-973
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.Lancet. 2011; 377: 2181-2192
- Ezetimibe added to statin therapy after acute coronary syndromes.N Engl J Med. 2015; 372: 2387-2397
- Lipid-lowering therapy in persons with chronic kidney disease.Ann Intern Med. 2012; 157: 251-262
- High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.Circulation. 1989; 79: 8-15
- Cholesteryl ester transfer protein inhibition: effect on reverse cholesterol transport?.Arterioscler Thromb Vasc Biol. 2006; 26: 681-684
- Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.N Engl J Med. 2007; 356: 1620-1630
- Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.Lancet. 2007; 370: 153-160
- Effect of torcetrapib on the progression of coronary atherosclerosis.N Engl J Med. 2007; 356: 1304-1316
- Effects of torcetrapib in patients at high risk for coronary events.N Engl J Med. 2007; 357: 2109-2122
- Safety and efficacy of dalcetrapib on atherosclerotic disease using non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.Lancet. 2011; 378: 1547-1559
- Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.Eur Heart J. 2012; 33: 857-865
- Effects of dalcetrapib in patients with a recent acute coronary syndrome.N Engl J Med. 2012; 367: 2089-2099
- Safety of anacetrapib in patients with or at high risk for coronary heart disease.N Engl J Med. 2010; 363: 2406-2415
- Biochemical characterization of cholesteryl ester transfer protein inhibitors.J Lipid Res. 2010; 51: 2739-2752
- Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.Lancet. 2007; 370: 1907-1914
- Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.Am Heart J. 2009; 157: 352-360
- Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.J Lipid Res. 2011; 52: 2169-2176
- Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.JAMA. 2011; 306: 2099-2109
- The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.Proc Natl Acad Sci USA. 2003; 100: 928-933
- Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.Coron Artery Dis. 2014; 25: 353-359
- Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment.Vascul Pharmacol. 2014; 62: 94-102
- Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia.Am J Cardiol. 2015; 115: 178-182
- PCSK9: From discovery to therapeutic applications.Arch Cardiovasc Dis. 2014; 107: 58-66
- The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway.Atherosclerosis. 2013; 228: 18-28
- Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.Lancet. 2012; 380: 29-36
- Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.N Engl J Med. 2012; 367: 1891-1900
- Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.J Am Coll Cardiol. 2012; 59: 2344-2353
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.Lancet. 2012; 380: 2007-2017
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.Lancet. 2012; 380: 1995-2006
- Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.JAMA. 2012; 308: 2497-2506
- Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial.Circulation. 2012; 126: 2408-2417
- Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia.Am J Cardiol. 2015; 115: 1212-1221
- Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.N Engl J Med. 2015; 372: 1489-1499
- Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.N Engl J Med. 2015; 372: 1500-1509